Ami Fadia, an analyst from Needham, maintained the Buy rating on Jazz Pharmaceuticals. The associated price target remains the same with $202.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ami Fadia’s rating is based on Jazz Pharmaceuticals’ strategic launch of Modeyso, which has been approved for treating H3-K27M diffuse midline glioma in both adult and pediatric patients. This approval marks a significant milestone for the company, as the condition is ultra-rare, with an annual incidence of approximately 2,000 cases in the US. Jazz’s management has effectively targeted key healthcare professionals through a combination of in-person and non-personal promotional efforts, aiming to maximize Modeyso’s reach and impact.
Additionally, Jazz is advancing its global Phase 3 ACTION study for first-line patients, which has already reached over 50% enrollment. This ongoing research effort underscores Jazz’s commitment to expanding its therapeutic offerings and addressing unmet medical needs. The combination of these strategic initiatives and the potential for Modeyso to capture a niche market supports the optimistic outlook and the Buy rating assigned by Ami Fadia.
According to TipRanks, Fadia is a 4-star analyst with an average return of 8.3% and a 50.55% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Axsome Therapeutics, and Immuneering.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $163.00 price target.